Merck KGaA announced detailed results of the two-year (96-week) placebo-controlled CLARITY (1) Phase III trial using Cladribine Tablets (Merck’s proprietary investigational oral formulation of cladribine) to treat patients with relapsing-remitting multiple sclerosis (MS). pharmaceutical medicine
New Phase III results presented at the American Academy of Neurology (AAN) congress show that 80-83% of patients taking FTY720 (fingolimod), an investigational oral compound for relapsing-remitting multiple sclerosis, remained free of relapses during the one-year study compared to 69% of those on interferon beta-1a[2], an established standard of care[3] (p pharmaceutical medicine
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced results from several new clinical and preclinical studies providing further insight on the immunomodulatory mechanism of action (MOA) of laquinimod, a novel oral once-daily compound being developed for the treatment of relapsing-remitting multiple sclerosis (RRMS). pharmaceutical medicine
Pharmaceutical MedicineThe definitive guide to developments in pharmaceutical medicine . Access the latest, most trusted scientific, medical and academic research journals.
Pharmaceutical & Medicine ManufacturingAmazon Botanicals manufactures Amazon Raintree herbs and remedies. We are committed to providing cutting edge Amazon herbs and herbal formulas. Products currently manufactured .
